# Alkem Laboratories (ALKEM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/alkem

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹5,297
- Change: +2.06%
- As of: 2026-11-06
- 1D return: +2.06%
- 5D return: +3.59%
- 1M return: +0.90%
- Latest complete quarter: fy26_q4

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

ALKEM presents a mixed technical picture as of November 6, 2026, with the stock trading at ₹5,190. On the daily horizon, the setup is bearish; price action sits below the Supertrend and key moving averages (50-day EMA/SMA, 200-day SMA), indicating short-term weakness despite being above the 20-day EMA and SMA. Trend strength is weak on the daily (ADX 17.57) and weekly (ADX 12.93) timeframes, suggesting a lack of decisive momentum. However, the monthly trend remains bullish with a developing ADX of 22.32, and the price is positioned in the upper-middle of its 20-day range (+63.6%) while remaining in the lower-middle of its 252-day range (+33.8%).

Recent activity shows high participation without clear direction on November 5 (-0.5% return) and a wide intraday range on October 22. The stock has experienced a current drawdown of -11.9% against a maximum historical drawdown of -18.2%, with annualized volatility at +22.4%. Immediate resistance lies near the pivot at ₹5,195.83 (0.11% above) and the high at ₹5,250.67 (1.17% above). Support is found at ₹5,161.67 (0.55% below) and ₹5,132.82 (1.10% below). A break above the immediate pivot resistance could signal a shift toward the stronger monthly bullish structure, while a close below recent support levels would reinforce the daily bearish bias.

- Timeframe Conflict: Daily and weekly trends are bearish (price below Supertrend and most MAs), but the monthly trend remains bullish with an ADX of 22.32.
- Weak Momentum: Daily ADX is 17.57 and weekly ADX is 12.93, indicating low trend conviction and choppy price action.
- Key Levels: Immediate resistance at ₹5,195.83 (pivot) and ₹5,250.67 (high); support at ₹5,161.67 (low) and ₹5,132.82 (low).
- Risk Profile: Current drawdown is -11.9% from available highs, with annualized volatility at +22.4% and ATR at 2.32%.

- Inside Bar
- Doji
- Bullish Engulfing Reversal
- Morning Star
- Outside Bar

### News Context

Alkem Laboratories is undergoing a leadership transition with the appointment of Amrut Naik as Chief Executive Officer, effective November 11, 2026. This change follows board approval and nomination committee recommendations, placing a leader with over 26 years of experience in pharmaceuticals and biologics at the helm. The appointment occurs against a backdrop of strong sector performance; India’s pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date. Analysts attribute this outperformance to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide. While some analysts view the rally as sustainable due to predictable earnings, they caution that valuations may limit further market-beating gains compared to other sectors.

- Amrut Naik appointed CEO effective November 11, 2026, bringing over 26 years of pharma/biologics experience.
- Indian pharma sector index up 27% year-to-date in 2026, led by stocks like Laurus Labs (up to 112%).
- Sector growth driven by domestic demand, US margin improvement, and semaglutide opportunities.
- Analysts note potential valuation constraints on future outperformance despite earnings predictability.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Alkem Laboratories appoints Amrut Naik as CEO](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alkem-laboratories-appoints-amrut-naik-as-ceo/articleshow/135494576.cms)

### Official Filings

Alkem Laboratories Limited has filed two material developments with the NSE and BSE. First, the Board approved the appointment of Dr. Amrut Naik as Chief Executive Officer (CEO) and Key Managerial Personnel, effective November 11, 2026. This leadership change will coincide with the company's upcoming financial disclosures for the half-year ended September 2026. Second, the US FDA concluded an inspection at Alkem’s API manufacturing facility in Mandva from October 26 to October 30, 2026, issuing no Form 483 observations. The absence of regulatory observations indicates compliance with US quality standards, which is a critical operational metric for pharmaceutical manufacturers exporting to the American market.

Investors should note that these events precede the scheduled Board Meeting on November 12, 2026, where standalone and consolidated unaudited financial results for Q2 and H1 FY27 will be considered. A virtual earnings call with analysts and institutional investors is also scheduled for November 12, 2026, at 16:30 IST, hosted by Motilal Oswal Securities Ltd., featuring Mr. Sandeep Singh, Dr. Amrut Naik, and Mr. Dishant Hitesh Doshi.

- Leadership Change: Dr. Amrut Naik appointed as CEO and KMP, effective November 11, 2026, following Board approval on November 3, 2026.
- Regulatory Compliance: US FDA inspection at the Mandva API facility (October 26–30, 2026) concluded with no Form 483 observations issued.
- Financial Reporting Schedule: Board Meeting scheduled for November 12, 2026, to approve unaudited financial results for the quarter and half-year ended September 30, 2026.
- Investor Engagement: Virtual conference call for Q2 and H1 FY27 results scheduled for November 12, 2026, at 16:30 IST.

- [Financial Results |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/ALKEM_04112026135715_Alkem-Notice_of_BM_September_2026_signed.pdf)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- [Board Meeting Intimation |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_161831376.xml)
- [Alkem Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ALKEM_04112026163623_IntimationforConCallInviti12112026_signed.pdf)
- [Alkem Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ALKEM_04112026165453_Intimation_for_ConCall_Invite-updated_signed.pdf)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_172933130.xml)
- [Alkem Laboratories Limited has informed the Exchange regarding Appointment of Dr. Amrut Naik as Chief Executive Officer (CEO) and Key Managerial Personnel of the company with effect from November 11, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/ALKEM_03112026133322_Reg30_Appointment_of_CEO_signed.pdf)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_13311_WebXMLFile_20261103_134838677.xml)
- [Alkem Laboratories Limited has informed the Exchange about US FDA Inspection at Company s API manufacturing facility located at Mandva. |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/ALKEM_30102026152036_Closure_of_USFDA_inspection_-Mandva-signed.pdf)

### Fundamentals

ALKEM Laboratories reported a sharp sequential deterioration in Q4 FY2025-26, with revenue from operations declining to ₹3,603.32 crore from ₹3,736.82 crore in Q3. Profit before tax fell significantly to ₹422.85 crore from ₹781.20 crore, driven by a rise in finance costs to ₹53.88 crore and other expenses increasing to ₹1,125.96 crore. Net profit contracted to ₹251.11 crore from ₹653.03 crore.

Despite this quarterly weakness, the annual trajectory remains robust. Sales grew 13.5% year-on-year to ₹14,712 crore for FY2025-26, while operating profit surged 19.8% to ₹3,007 crore. Net profit rose 6.2% to ₹2,351 crore, supporting an EPS of ₹192.51. Cash flow quality is strong, with cash from operating activities at ₹1,963 crore and CFO/EBITDA conversion at 86%. The balance sheet shows increased leverage, with borrowings rising to ₹2,047 crore from ₹1,381 crore, likely funding fixed asset expansion to ₹3,871 crore. Working capital efficiency has eased, with inventory days rising to 239 days and debtor days to 74 days.

The critical checkpoint is whether the company can stabilize margins and manage the higher interest burden as it integrates new capacity, given the recent sequential profit compression.

- Q4 FY2025-26 revenue fell sequentially to ₹3,603.32 crore, with net profit dropping sharply to ₹251.11 crore from ₹653.03 crore in Q3 due to higher finance and other expenses.
- FY2025-26 full-year sales grew 13.5% to ₹14,712 crore, and operating profit expanded 19.8% to ₹3,007 crore, maintaining strong annual growth momentum.
- Borrowings increased to ₹2,047 crore (from ₹1,381 crore in FY2025) as fixed assets grew to ₹3,871 crore; cash from operations remained healthy at ₹1,963 crore.
- Working capital cycles have lengthened, with inventory days rising to 239 and debtor days to 74, requiring monitoring of liquidity management.

### Bear Case

Alkem Laboratories faces near-term technical weakness and underperformance relative to its sector peers. As of November 5, 2026, the stock is trading at ₹5,190, reflecting a year-to-date decline of 5.0% and a one-year return of -8.4%. Technical indicators on daily and weekly timeframes are bearish, with the Supertrend direction signaling downside pressure and moving averages (SMA 20 and SMA 50) sloping negatively. The stock is currently in an 11.9% drawdown from its peak, with a maximum historical drawdown of 18.2%, indicating significant volatility and recent selling pressure. While the broader Indian pharmaceutical sector has rallied 27% year-to-date, Alkem’s performance lags, suggesting specific headwinds or lack of momentum compared to peers like Laurus Labs. A new CEO appointment effective November 11 introduces a leadership transition period, which may contribute to short-term uncertainty as the market assesses strategic continuity.

- Technical breakdown: Daily and weekly Supertrends are bearish; SMA 20 (-15.38 slope) and SMA 50 (-21.93 slope) indicate sustained downward momentum.
- Underperformance: Year-to-date return is -5.0% and one-year return is -8.4%, lagging the sectoral index rise of 27%.
- Volatility risk: Current drawdown stands at -11.9% against a maximum drawdown of -18.2%; annualized volatility is +22.4%.
- Leadership transition: New CEO Amrut Naik takes effect on November 11, 2026, introducing a period of executive change.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Alkem Laboratories appoints Amrut Naik as CEO](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alkem-laboratories-appoints-amrut-naik-as-ceo/articleshow/135494576.cms)
- [Financial Results |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/ALKEM_04112026135715_Alkem-Notice_of_BM_September_2026_signed.pdf)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- [Board Meeting Intimation |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_161831376.xml)
- [Alkem Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ALKEM_04112026163623_IntimationforConCallInviti12112026_signed.pdf)
- [Alkem Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ALKEM_04112026165453_Intimation_for_ConCall_Invite-updated_signed.pdf)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_172933130.xml)
- [Alkem Laboratories Limited has informed the Exchange regarding Appointment of Dr. Amrut Naik as Chief Executive Officer (CEO) and Key Managerial Personnel of the company with effect from November 11, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/ALKEM_03112026133322_Reg30_Appointment_of_CEO_signed.pdf)

### FAQs

**When will Alkem Laboratories release its Q2 and H1 FY27 financial results?**

Alkem Laboratories has scheduled a Board of Directors meeting for Thursday, 12 November 2026. The board will consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2026.

**Who is leading Alkem Laboratories following recent leadership changes?**

Amrut Naik has been appointed as the new Chief Executive Officer, effective 11 November 2026. He brings over 26 years of experience in pharmaceuticals and biologics, holding advanced degrees in pharmaceutical science and pharmacology.

**What are the key dates and details for the upcoming investor call?**

A virtual conference call to discuss Q2FY27 and H1FY27 results is scheduled for 12 November 2026 at 4:30 PM IST. The call will be hosted by Motilal Oswal Securities Ltd., with representation from Managing Director Mr. Sandeep Singh, CEO Dr. Amrut Naik, and Deputy CFO Mr. Dishant Hitesh Doshi.

**How has Alkem's stock performance tracked recently against sector trends?**

As of 5 November 2026, Alkem's share price closed at ₹5,190.00, reflecting a -8.4% return over the past year and a -5.0% year-to-date decline. This contrasts with the broader Indian pharmaceutical sector, which rose 27% year-to-date in 2026, driven by resilient domestic demand and improving US business margins.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Alkem Laboratories appoints Amrut Naik as CEO](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alkem-laboratories-appoints-amrut-naik-as-ceo/articleshow/135494576.cms)
- [Financial Results |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/ALKEM_04112026135715_Alkem-Notice_of_BM_September_2026_signed.pdf)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- [Board Meeting Intimation |Meeting Date: 12-Nov-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_161831376.xml)
- [Alkem Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ALKEM_04112026163623_IntimationforConCallInviti12112026_signed.pdf)
- [Alkem Laboratories Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/ALKEM_04112026165453_Intimation_for_ConCall_Invite-updated_signed.pdf)
- [ALKEM LABORATORIES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_172933130.xml)
- [Alkem Laboratories Limited has informed the Exchange regarding Appointment of Dr. Amrut Naik as Chief Executive Officer (CEO) and Key Managerial Personnel of the company with effect from November 11, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/ALKEM_03112026133322_Reg30_Appointment_of_CEO_signed.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹5,192
- Risk regime: Price Risk Currently Contained

### Support levels
- 5199
- 5132.81611328125
- 4815.9234375

### Resistance levels
- 5423.013137817383
- 5502.796875
- 5660.169177246094

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +2.06% |
| return_10 | +7.07% |
| return_1m | +0.09% |
| return_1y | -6.14% |
| return_20 | +0.90% |
| return_3m | -5.37% |
| return_5 | +3.59% |
| return_6m | -4.68% |
| return_since_start | -4.92% |
| return_ytd | -3.05% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -18.21% |
| annualized_volatility | +22.46% |

## Quarterly financials

- Latest complete quarter: fy26_q4

# Rising expenses and higher taxes cut profit despite revenue growth

In the fourth quarter of FY2025–26, Alkem Laboratories reported a 14.6% year-on-year increase in revenue, but net profit fell 22.1%. The decline was driven by a sharp rise in other operating expenses, sustained growth in finance costs, and a substantially higher tax charge. Both revenue and profit also declined sequentially from the preceding quarter, with the drop in net profit particularly steep.

## Revenue and Profit Trends

Revenue from operations stood at ₹3,603.32 crore, up from ₹3,143.75 crore a year earlier and down from ₹3,736.82 crore in the prior quarter. Profit before tax came in at ₹422.85 crore, an increase of 6.7% year-on-year but a decrease of 45.9% sequentially. Net profit fell to ₹251.11 crore, marking a 22.1% year-on-year decline and a 61.5% sequential drop. The divergence between top-line growth and bottom-line contraction defines the quarter’s financial result.

## Cost Structure and Expense Growth

Total expenses, calculated as revenue plus other income minus profit before tax, amounted to ₹3,380.54 crore. The sum of five disclosed cost categories—cost of materials consumed (₹894.94 crore), employee benefit expense (₹712.10 crore), finance costs (₹53.88 crore), depreciation (₹105.76 crore), and other expenses (₹1,125.96 crore)—totalled ₹2,892.64 crore. The remaining ₹487.90 crore, representing 14.4% of total expenses, is attributable to other cost items not explicitly broken out in the company’s quarterly reporting.

Other expenses, the largest single category, rose 31.4% year-on-year and 23.1% sequentially, growing faster than revenue and directly limiting profit expansion. Finance costs have risen for five consecutive quarters, reaching ₹53.88 crore, an 89.6% increase over the prior-year quarter and a 28.0% sequential rise. Cost of materials consumed accounted for 24.8% of revenue, employee benefits for 19.8%, and depreciation for 2.9%.

## Tax Expense and Effective Tax Rate

Tax expense for the quarter was ₹171.17 crore, more than double the ₹73.33 crore recorded a year earlier and 34.1% above the prior quarter. This resulted in an effective tax rate of 40.5%, compared with 18.5% a year ago and 16.3% in Q3 FY2025–26. The year-on-year increase in tax expense totalled ₹97.84 crore, directly reducing the profit for the period.

## Earnings Per Share

Basic and diluted earnings per share were both ₹19.77, down 22.7% from ₹25.57 a year earlier and 62.8% from ₹53.19 in the preceding quarter. The movement aligns precisely with the net profit decline.

## Key Takeaway

In Q4 FY2025–26, a sharp increase in other operating expenses, rising finance costs, and an elevated effective tax rate combined to push net profit 22.1% lower year-on-year, despite a 14.6% increase in revenue. The sequential fall was even steeper, with net profit declining 61.5% from the preceding quarter. The quarter’s performance highlights how rapid expense growth and higher tax charges can offset top-line gains, resulting in a significant contraction in reported earnings.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +49.70%
- FII holding: +10.42%
- DII holding: +22.64%
- Mutual fund holding: +16.71%
- Retail holding: +1.15%
- Promoter pledged: +0.00%

### Major reported shareholders

- Sarandhar Singh * (please refer notes) — +18.29%
- Basudeo Narain Singh — +7.27%
- Mritunjay Kumar Singh — +6.42%
- Madhurima  Singh& (please refer notes) — +6.18%
- Hdfc Mutual Fund - Hdfc Mid-Cap Fund — +4.77%
- Icici Prudential Multi-Asset Fund — +3.57%
- Madhurima  Singh@ (please refer notes) — +2.59%
- Kishor  Kumar Singh — +2.49%
- Alok  Kumar — +2.31%
- Ashok Kumar — +2.25%

## Official filings

- 2026-11-04 — Board Meeting Notice: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_04112026135715_Alkem-Notice_of_BM_September_2026_signed.pdf)
- 2026-11-04 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- 2026-11-04 — Board Meeting Notice: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_13311_WebXMLFile_20261104_140743603.xml)
- 2026-11-04 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_161831376.xml)
- 2026-11-04 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_04112026163623_IntimationforConCallInviti12112026_signed.pdf)
- 2026-11-04 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_04112026165453_Intimation_for_ConCall_Invite-updated_signed.pdf)
- 2026-11-04 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_13311_WebXMLFile_20261104_172933130.xml)
- 2026-11-03 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_03112026133322_Reg30_Appointment_of_CEO_signed.pdf)
- 2026-11-03 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_13311_WebXMLFile_20261103_134838677.xml)
- 2026-10-30 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_30102026152036_Closure_of_USFDA_inspection_-Mandva-signed.pdf)
- 2026-10-21 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_21102026215316_Reg30Disclosurefinalsigned.pdf)
- 2026-10-12 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_12102026160820_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf)
- 2026-10-12 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_12102026160911_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf)
- 2026-10-12 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_13311_WebXMLFile_20261012_161149404.xml)
- 2026-09-24 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_24092026124110_Reg30Intimation_signed.pdf)
- 2026-09-24 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_ROID_98892_KMP_Doc.zip)
- 2026-09-23 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_23092026141947_ScheduleofInvestorMeet_Oct_2026_signed.pdf)
- 2026-09-22 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_22092026172602_Closure_of_trading_window_Intimation-_September_2026_signed.pdf)
- 2026-09-22 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_13311_WebXMLFile_20260922_174119193.xml)
- 2026-09-21 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_21092026173921_Reg_30_disclosure_signed.pdf)
- 2026-09-21 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_13311_WebXMLFile_20260921_181958146.xml)
- 2026-09-16 — Press Release: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf)
- 2026-09-15 — Management Change: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_15092026210812_Reg_30.pdf)
- 2026-09-15 — Generic Announcement: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_13311_WebXMLFile_20260915_213337240.xml)
- 2026-09-08 — Press Release: Alkem Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/ALKEM_08092026150801_Intimation_signed.pdf)

## News and market events

- 2026-11-07 — The Hindu: **Tech Query: Alkem Laboratories, Intellect Design Arena, Trent, SRF — What is the outlook? Where are these stocks headed?** — BL Research Bureau provided technical analysis and trading recommendations for Alkem Laboratories, Intellect Design Arena, Trent, and SRF, suggesting accumulation or holding for Alkem, Trent, and SRF while advising exit for Intellect Design Arena due to a reversed uptrend. — [Source](https://www.thehindubusinessline.com/portfolio/technical-analysis/tech-query-alkem-laboratoriesintellect-design-arena-trent-srf-what-is-the-outlook-where-are-these-stocks-headed/article71674469.ece)
- 2026-11-05 — Economic Times: **Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return** — India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- 2026-11-03 — Economic Times: **Alkem Laboratories appoints Amrut Naik as CEO** — Alkem Laboratories has appointed Amrut Naik as its new Chief Executive Officer, effective November 11, following board approval and nomination committee recommendations. Naik brings over 26 years of experience in pharmaceuticals and biologics, holding advanced degrees in pharmaceutical science and pharmacology. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alkem-laboratories-appoints-amrut-naik-as-ceo/articleshow/135494576.cms)
- 2026-10-27 — BUSINESSTODAY: **Alkem’s Madhurima Singh on scaling businesses and building stronger teams** — Balancing the demands of an established pharmaceutical business with the pursuit of new opportunities in healthcare defines Madhurima Singh’s approach to leadership.As Executive Director of Alkem Laboratories, she is focused on building new capabilities and aligning teams to expand the company’s ambitions beyond its core business, while ensuring its legacy remains a foundation for growth rather than a constraint.That means investing in new capabilities, bringing different teams together, and ensuring that the company’s legacy does not limit its ambitions. — [Source](https://www.businesstoday.in/magazine/profile/story/alkems-madhurima-singh-on-scaling-businesses-and-building-stronger-teams-564109-2026-10-27)
- 2026-09-29 — Mint: **Top stocks to buy or sell in F&O segment: Alkem Lab, KFin Tech, Amber Ent by Jay Thakkar - Check short-term targets** — Indian equity markets continued to decline as geopolitical tensions raised oil prices and bond yields. The Nifty 50 fell 0.28% to 22,716.2, while the Sensex slid 0.33%. The indices have lost nearly 6% over seven weeks, marking an extended losing streak amid volatility. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-to-buy-or-sell-in-f-o-segment-alkem-lab-kfin-tech-amber-ent-by-jay-thakkar-check-short-term-targets-11790681511028.html)
- 2026-09-25 — Economic Times: **Alkem Laboratories CFO Nitin Agrawal resigns** — Alkem Laboratories CFO and Key Managerial Personnel Nitin Agrawal has resigned from the drug maker to pursue new professional opportunities, the company said in a regulatory filing. Agrawal will step down from his senior management position effective September 30, 2026. He cited long-term professional and personal growth in his resignation letter. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alkem-laboratories-cfo-nitin-agrawal-resigns/articleshow/134480273.cms)
- 2026-09-24 — MONEYCONTROL: **Alkem Laboratories shares fall over 2% after CFO Nitin Agrawal resigns** — Alkem Laboratories, Alkem Laboratories stocks, Alkem Laboratories shares, Alkem Laboratories shares, Alkem Laboratories Nitin Agrawal — [Source](https://www.moneycontrol.com/news/business/stocks/alkem-laboratories-shares-fall-over-2-after-cfo-nitin-agrawal-resigns-14037246.html)
- 2026-09-22 — REDIFF.COM: **Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies** — India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies. — [Source](https://www.rediff.com/business/report/indias-top-10-pharma-companies-sustain-volume-growth-outperforming-smaller-rivals/20260922.htm)
- 2026-09-17 — BUSINESS: **Quick Wrap: Nifty Pharma Index rises 1.66%** — Powered by Capital Market - Live News — [Source](https://www.business-standard.com/markets/capital-market-news/quick-wrap-nifty-pharma-index-rises-1-66-126091700943_1.html)
- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-17 — BUSINESS: **Alkem Laboratories Ltd spurts 2.36%** — Alkem Laboratories Ltd is quoting at Rs 5297, up 2.36% on the day as on 12:49 IST on the NSE. The stock is down 3.33% in last one year as compared to a 8.21% drop in NIFTY and a 17.44% drop in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/alkem-laboratories-ltd-spurts-2-36-126091700511_1.html)
- 2026-09-16 — The Hindu: **Alkem Laboratories launches NeuCeno cenobamate for epilepsy in India** — Alkem Laboratories has launched NeuCeno (cenobamate) in India for adult patients with partial-onset seizures, available in strengths from 12.5 mg to 200 mg. — [Source](https://www.thehindubusinessline.com/companies/alkem-laboratories-launches-neuceno-for-partial-onset-seizures-in-adults/article71473899.ece)
- 2026-09-16 — BUSINESS: **Benchmarks recover after recent sell-off; Nifty ends above 23,200** — The key equity benchmarks ended higher on Wednesday, snapping a two-session losing streak. Gains followed a pause in crude oil prices and a marginal easing in global bond yields. — [Source](https://www.business-standard.com/markets/capital-market-news/benchmarks-recover-after-recent-sell-off-nifty-ends-above-23-200-126091600881_1.html)
- 2026-09-16 — BUSINESS: **Indices snap 2-day losses; FMCG shares rally** — As per provisional closing data, the barometer index, the S&P BSE Sensex jumped 332.63 points or 0.45% to 74,336.45. The Nifty 50 index added 99 points or 0.43% to 23,217.60. In the past two consecutive trading sessions the Sensex and Nifty declined 1.20% and 1.53%, respectively. — [Source](https://www.business-standard.com/markets/capital-market-news/indices-snap-2-day-losses-fmcg-shares-rally-126091600763_1.html)
- 2026-09-16 — BUSINESS: **Nifty holds above 23,250 level; European shares trade mostly in green** — The benchmark indices traded near the day's high in afternoon trade, tracking positive cues from Asian markets as the recent rally in crude oil prices paused. Investors remained cautious ahead of the US Federal Reserves policy meeting later today. The Nifty surged above the 23,250 mark, indicating some recovery in market sentiment. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-holds-above-23-250-level-european-shares-trade-mostly-in-green-126091600540_1.html)
- 2026-09-16 — BUSINESS: **Alkem Labs launches epilepsy management drug Cenobamate in India** — Alkem Laboratories has announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. — [Source](https://www.business-standard.com/markets/capital-market-news/alkem-labs-launches-epilepsy-management-drug-cenobamate-in-india-126091600477_1.html)
- 2026-09-08 — CNBC-TV18: **Alkem launches India’s first patented ginsenoside exosome-based hair growth serum** — Alkem Laboratories has launched Renocia Exo™, a hair regeneration serum combining ginsenoside phyto-exosomes, biomimetic peptides, copper peptides and stem cell-supportive actives. — [Source](https://www.cnbctv18.com/business/companies/alkem-launches-indias-first-patented-ginsenoside-exosome-based-hair-growth-serum-19986670.htm)
- 2026-09-01 — The Hindu: **Broker’s Call: Alkem Laboratories (Buy)** — Elara Securities — [Source](https://www.thehindubusinessline.com/markets/brokers-call-alkem-laboratories-buy/article71414475.ece)
- 2026-08-18 — BUSINESS: **Volumes spurt at Billionbrains Garage Ventures Ltd counter** — Billionbrains Garage Ventures Ltd notched up volume of 819.05 lakh shares by 10:46 IST on BSE, a 44.78 fold spurt over two-week average daily volume of 18.29 lakh shares — [Source](https://www.business-standard.com/markets/capital-market-news/volumes-spurt-at-billionbrains-garage-ventures-ltd-counter-126081800352_1.html)
- 2026-08-17 — CNBC-TV18: **Five reasons behind Investec's upgrade of Alkem Labs, and why JPMorgan is cautious** — 60% of the analysts who have coverage on Alkem Laboratories have a "buy" recommendation, while the rest are either "neutral" or have a "sell" rating on the stock. — [Source](https://www.cnbctv18.com/market/alkem-labs-share-price-investec-upgrade-q1-results-key-factors-macquarie-jpm-cautious-buy-sell-19970590.htm)
- 2026-08-17 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: GIFT Nifty trades 50 pts lower; M&M in focus** — Stock Market Live Updates: The Nifty has been grinding lower even as it consolidates in a narrow range. The index has lost 300 points in the last six sessions, despite a better-than-expected earnings season. Oil prices remain near $90 a barrel. Watch for movements on the USD-INR and further block deal announcements. Watch this space for all the LIVE stock market updates, management commentary and stocks in news. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-reliance-hdfc-bank-cochin-nmdc-voltas-gmr-jupiter-share-price-liveblog-19970547.htm)
- 2026-08-14 — The Hindu: **Q1 Results Today Live: BDL, Ashok Leyland, 3M India Q1 PAT rise y-o-y, Electrotherm, NATCO Pharma, Alkem Lab PAT decline, NMDC, Voltas, Cochin Shipyard, Physicswallah, PTC Ind, Borosil to announce Q1 results** — Q1 Results Today, 14th August 2026 Live Updates:  Follow Q1FY27 live updates from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-ashok-leylad-nmdc-alkem-lab-bharat-dynamics-voltas-3m-india-cochin-shipyard-physicswallah-cholamandalam-fin-ptc-ind-natco-pharma-tmpv-results-14-august-2026/article71340415.ece)
- 2026-08-14 — The Hindu: **Sensex today | Stock Market Live: Sensex off day's low, down 118 pts; Nifty below 24,400 as West Asia worries weigh** — Sensex, Nifty, Share Prices LIVE:  Indian equities remained subdued in noon trade on Friday, with persistent West Asia tensions and continued foreign selling weighing on sentiment. Easing expectations of a September US Fed rate hike and softer crude prices offered limited support, restricting the market’s decline. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-14th-august-2026/article71341547.ece)
- 2026-08-14 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty Auto down about 140 points; Tata Motors PV leads loses** — Sensex Today | Stock Market LIVE Updates: We are the half way mark of the day's trade and the markets remain in red. The markets are under pressure, with the Nifty index falling towards the 24,300 mark. The Nifty Bank is also trading on similar ground, falling below the 57,500 mark. Tata Motors PV, Hindalco, Max Health are the top losers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-sensex-hdfc-bank-nifty-bank-q1-earnings-tata-motors-max-fin-defence-bdl-share-price-liveblog-19969121.htm)
- 2026-08-14 — CNBC-TV18: **Alkem Labs Q1 Results: Shares down 3% after profit falls; revenue rises 11%** — Alkem Laboratories MD Sandeep Singh said the company had started FY27 on a steady note, with healthy growth across its India and international businesses. He said the India business continued to outperform the market, while growth in non-US international markets remained encouraging. — [Source](https://www.cnbctv18.com/market/alkem-labs-q1-results-shares-down-profit-falls-revenue-rises-india-business-non-us-international-markets-19969594.htm)

## Business profile

**Strategic vision:** Multinational pharmaceutical company developing, manufacturing, and selling pharmaceutical products.

### Business segments
- **Prescription Products (Rx):** Focuses on branded generic formulations across various acute and chronic therapeutic areas.
- **Alkem Generics:** A trade generics division catering to domestic market segments, comprising sub-divisions such as Futura, Maxxio, and Novokem.
- **Active Pharmaceutical Ingredients (APIs):** Handled by the Alkem Activa division, which synthesizes APIs for captive consumption and commercial supply.
- **Biosimilars and MedTech:** Develops biosimilars through its subsidiary Enzene Biosciences, alongside medical technology solutions in cardiology and orthopedics.

### Competitive strengths
- Integrated operations across R&D, API synthesis, formulation manufacturing, and distribution.
- Diversified business model balancing domestic and international markets.
- Strong presence in key therapeutic segments.
- Regulatory compliance with global agencies.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/alkem
Markdown representation: https://faxioms.com/stocks/alkem?render=md